Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.44 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.41 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | EDNRA | P25101 | 1/20 | 0.38 |
| ▸ | HPGDS | O60760 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527502 | 1.00 | OPRK1 (0.44) | OPRK1CNR2ULK1PRKAA2PRKAA1 | |
| SCHEMBL29457453 | 0.83 | OPRK1 (0.49) | OPRK1HSD17B10 | |
| SCHEMBL757419 | 0.83 | OPRK1 (0.49) | OPRK1HSD17B10 | |
| SCHEMBL16142840 | 0.83 | CNR2 (0.42) | OPRK1CNR2NPC1RAB9AHPGDS | |
| SCHEMBL611999 | 0.83 | CNR2 (0.47) | OPRK1CNR2NPC1RAB9AHPGDS | |
| SCHEMBL3376053 | 0.82 | SCN9A (0.44) | CNR2 | |
| SCHEMBL316314 | 0.81 | HSD17B10 (0.50) | OPRK1CNR2LMNAKDM4EALDH1A1 | |
| SCHEMBL14764185 | 0.81 | HTT (0.44) | OPRK1CNR2NPC1RAB9AALDH1A1 | |
| SCHEMBL15228274 | 0.81 | CNR2 (0.46) | OPRK1CNR2KDM4EALDH1A1HPGD | |
| SCHEMBL30989984 | 0.81 | PTGER4 (0.42) | NPC1RAB9ANUDT1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108137542-B | Pyridone dicarboxamides as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2023-10-27 | — | — | CN | disclosed |
| US-11786532-B2 | 2-pyridones and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| CN-116710443-A | 2-pyridones as thyroid hormone receptor modulators | 阿利戈斯治疗公司 | 2023-09-05 | — | — | CN | disclosed |
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| CN-108137541-B | Pyridone dicarboxamides for use as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2021-07-06 | — | — | CN | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2021-02-23 | — | — | US | disclosed |
| CN-108290866-B | 2-oxo-1, 2-dihydropyridine-3, 5-dicarboxamide compounds as bromodomain inhibitors | 葛兰素史克知识产权第二有限公司 | 2020-12-18 | — | — | CN | disclosed |
| EP-3359531-B1 | 2-OXO-1,2-DIHYDROPYRIDINE-3,5-DICARBOXAMIDE COMPOUNDS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-08-19 | — | — | EP | disclosed |
| EP-3359531-B1 | 2-OXO-1,2-DIHYDROPYRIDINE-3,5-DICARBOXAMIDE COMPOUNDS AS BROMODOMAIN INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2020-08-19 | — | — | EP | disclosed |
| US-20120238579-A1 | New Compounds 806 | BESIDKI YEVGENI (SE) | 2012-09-20 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-8143408-B2 | N-(8-heteroaryltetrahydronaphtalene-2yl) or N-(5-heteroarylchromane-3-yl) carboxamide derivatives for the treatment of pain | ASTRAZENECA AB (SE) | 2012-03-27 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | US | disclosed |
| EP-2158198-A2 | NOVEL N- (8HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130320-A2 | NOVEL N- (8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N- (5- HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137322-A1 | NOVEL N-(8-HETEROARYLTETRAHYDRONAPHTALENE-2YL) OR N-(5-HETEROARYLCHROMANE-3-YL) CARBOXAMIDE DERIVATIVES FOR THE TREATMENT OF PAIN | OPRL1, OPRK1, OPRD1 | OPRK1 2/4885CNR2 4/4885ULK1 4138/4885 |
| US-20220143032-A1 | 2-PYRIDONES AND METHODS OF USE THEREOF | PSEN2, MAPT, PNPO | OPRK1 1295/4885CNR2 590/4885ULK1 1226/4885 |
| US-11786532-B2 | 2-pyridones and methods of use thereof | PSEN2, MAPT, PNPO | OPRK1 1295/4885CNR2 590/4885ULK1 1226/4885 |
| US-20120238579-A1 | New Compounds 806 | CYP2B6, CYP11B2, NDUFS6 | OPRK1 1328/4885CNR2 602/4885ULK1 3534/4885 |
| US-10927080-B2 | Pyridinone dicarboxamide for use as bromodomain inhibitors | BRD4, BRD3, BRDT | OPRK1 2107/4885CNR2 144/4885ULK1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.